A pilot study of long-acting octreotide for symptomatic malignant ascites.

Oncology
Aminah JatoiLynn C Hartmann

Abstract

Effective, non-invasive, palliative strategies for symptomatic malignant ascites are unavailable. This trial explored whether octreotide, an inhibitor of vascular endothelial growth factor, a putative mediator of ascites, prolongs the interval to next paracentesis. After a baseline paracentesis and a test of short-acting agent, patients with symptomatic ascites were randomly assigned to long-acting octreotide (Sandostatin LAR®) depot 30 mg intramuscularly every month versus 0.9% sodium chloride administered similarly. Patients were then monitored for recurrent, symptomatic ascites. Thirty-three patients were enrolled: 16 assigned to the octreotide and 17 to the control arm. The median time to next paracentesis was 28 and 14 days in the octreotide and placebo arm, respectively (p = 0.17). After adjustment for extracted ascites volume and abdominal girth change, no statistically significant difference between the groups was observed (hazard ratio = 0.52, with a 95% confidence interval of 0.21-1.28; p = 0.15, per Cox model). Octreotide-treated patients described less of abdominal bloating (p = 0.01), abdominal discomfort (p = 0.02), and shortness of breath (p = 0.007) at one month, although other quality of life symptoms were comp...Continue Reading

References

Apr 13, 2000·Journal of Pain and Symptom Management·J R MackeyP Venner
Apr 24, 2003·Clinical Oncology : a Journal of the Royal College of Radiologists·E M Smith, G C Jayson
Sep 19, 2003·Gynecologic Oncology·Vivian E von GruenigenKaren M Gil
Sep 28, 2005·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·C-H LinP C-I Ko
Dec 21, 2005·Journal of Cellular and Molecular Medicine·Anne Marie ByrneJ H Harmey
May 24, 2006·Scandinavian Journal of Gastroenterology·Rupert W L Leong, Gary P Jeffrey
Apr 5, 2008·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Karl-Heinz SchulzZobair M Younossi
May 18, 2010·International Journal of Cancer. Journal International Du Cancer·Markus M HeissSimon L Parsons
Aug 18, 2010·Journal of Palliative Medicine·Karen LeBlanc, Robert M Arnold
Aug 18, 2010·Journal of Palliative Medicine·Karen LeBlanc, Robert M Arnold

❮ Previous
Next ❯

Citations

Feb 22, 2013·Nature Reviews. Cancer·Emma KippsStan B Kaye
Jun 3, 2014·Journal of Palliative Medicine·Govindarajan NarayananKatuzka Barbery
Nov 24, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Rumi HanadaRyoko Kawahara
Mar 28, 2018·Journal of Pain and Symptom Management·Masanori MoriAsao Ogawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Journal of Vascular and Interventional Radiology : JVIR
Stefanie RosenbergReed A Omary
Journal of Palliative Medicine
Karen LeBlanc, Robert M Arnold
Current Treatment Options in Oncology
Michael Chung, Peter Kozuch
© 2021 Meta ULC. All rights reserved